



UPDATE ON MYOCONDA SALE

Sydney, NSW, 19 March 2010 - Giaconda Limited (ASX:GIA) (the "Company") today announced that it has agreed to a request from Australian Medical Therapy Investments Pty Limited ("AMTI") to vary the terms of the Asset Purchase Agreement to postpone completion from Friday 19 March 2010 until 19 April 2010.

That agreement contemplates that the Myoconda intellectual property will be sold by the Company to AMTI for \$928,000 (ex GST) plus 5% of the net sales earned by AMTI from a commercialised treatment.

The Company will make a further announcement once the Asset Purchase Agreement has been completed.

CONTACTS:

Giaconda	AMTI
Patrick McLean CEO and acting Chairman	Colin Goldrick Managing Director
T: +61 02 9370 0069 O/S: +1 514 937 5440	T: +61 2 8246 6218
Mclean278@hotmail.com SKYPE: patricklockie	Colin.Goldrick@amti.com.au

GIACONDA LIMITED

Ground Floor, 44 East Street, Five Dock NSW 2046 Phone: [612] 9370 0069 Fax: [612] 9712 1469
email: info@giacondalimited.com ABN 68 108 088 517 www.giacondalimited.com